Radiotherapy of classic Kaposi's sarcoma in Taiwan, an area where classic Kaposi's sarcoma is not prevalent

被引:0
作者
Huang, Kuo-Ming
Hsu, Chih-Hung
Cheng, Jason Chia-Hsien
Lai, Ming-Kuen
Jeng, Shiu-Chen
Ting, Lai-Lei
Huang, Wen-Tao
机构
[1] Yuanpei Univ, Dept Radiol Technol, Hsinchu 300, Taiwan
[2] Natl Taiwan Univ Hosp, Div Radiat Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan
[5] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[6] Yuanpei Univ, Grad Inst Med Image, Hsinchu 300, Taiwan
关键词
Kaposi's sarcoma; radiotherapy; Aquaplast RT (TM); thermoplastic; bolus;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Classic Kaposi's sarcoma (KS), a neoplastic disease of vascular endothelial cells of the skin, is relatively prevalent in Eastern Europe and the Mediterranean region and radiation is one of the standard therapies. The clinical presentation and treatment results of classic KS from other regions have rarely been reported. Patients and Methods: Between 1994 and 2006, patients who had histologically confirmed KS and no immunodeficiency status due to human immunodeficiency virus infection or organ transplantation, and were treated with radiotherapy at Department of Oncology, National Taiwan University Hospital, Japan, were reviewed. Results: A total of 17 classic KS patients, with a median age of 69 years, were studied over a period of 12 years. All classic KS lesions involved lower extremities. Radiotherapy was delivered with either a Co-60 unit or a linear accelerator, with the most commonly prescribed treatment being 3 Gy per fraction to a total dose of 39 Gy. In addition, several techniques using bolus were adopted to improve the radiation distribution over the skin of lower extremities. All irradiated KS lesions responded, with a complete response rate of 76%. The overall survival and progression-free survival rates of the group at 5 years were 85% and 58%, respectively. Conclusion: Radiation therapy for classic KS patients in a non-prevalent area, such as Taiwan, is safe and effective.
引用
收藏
页码:4659 / 4663
页数:5
相关论文
共 19 条
  • [1] Kaposi's sarcoma
    Antman, K
    Chang, Y
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) : 1027 - 1038
  • [2] Brenner B, 1999, INT J ONCOL, V14, P1097
  • [3] Classical Kaposi sarcoma - Prognostic factor analysis of 248 patients
    Brenner, B
    Weissmann-Brenner, A
    Rakowsky, E
    Weltfriend, S
    Fenig, E
    Friedman-Birnbaum, R
    Sulkes, A
    Linn, S
    [J]. CANCER, 2002, 95 (09) : 1982 - 1987
  • [4] COMPARISON OF RADIATION-THERAPY OF CLASSIC AND EPIDEMIC KAPOSIS-SARCOMA
    CHANG, LFL
    REDDY, S
    SHIDNIA, H
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (03): : 200 - 206
  • [5] THE INFLUENCE OF DOSE ON THE LONG-TERM CONTROL OF CLASSIC (NON-AIDS ASSOCIATED) KAPOSIS SARCOMA BY RADIOTHERAPY
    COOPER, JS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (05): : 1141 - 1146
  • [6] KAPOSIS SARCOMA - AN UPDATE ON THE RESULTS OF EXTENDED FIELD RADIOTHERAPY
    HARWOOD, AR
    [J]. ARCHIVES OF DERMATOLOGY, 1981, 117 (12) : 775 - 778
  • [7] Hsu CH, 2000, ANTICANCER RES, V20, P1159
  • [8] Huang KM, 2006, ANTICANCER RES, V26, P759
  • [9] Iscovich J, 2000, CANCER-AM CANCER SOC, V88, P500, DOI 10.1002/(SICI)1097-0142(20000201)88:3<500::AID-CNCR3>3.3.CO
  • [10] 2-0